Literature DB >> 20541582

The potential value of Clostridium difficile vaccine: an economic computer simulation model.

Bruce Y Lee1, Michael J Popovich, Ye Tian, Rachel R Bailey, Paul J Ufberg, Ann E Wiringa, Robert R Muder.   

Abstract

Efforts are currently underway to develop a vaccine against Clostridium difficile infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer C. difficile vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer C. difficile vaccine to prevent CDI recurrence. Our results suggest that a C. difficile vaccine could be cost-effective over a wide range of C. difficile risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541582      PMCID: PMC2908196          DOI: 10.1016/j.vaccine.2010.05.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  Calculating QALYs, comparing QALY and DALY calculations.

Authors:  Franco Sassi
Journal:  Health Policy Plan       Date:  2006-07-28       Impact factor: 3.344

2.  Economics and preventing hospital-acquired infection: broadening the perspective.

Authors:  Nicholas Graves; Kate Halton; David Lairson
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

3.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile.

Authors:  Séverine Péchiné; Claire Janoir; Hélène Boureau; Aude Gleizes; Nicolas Tsapis; Sandra Hoys; Elias Fattal; Anne Collignon
Journal:  Vaccine       Date:  2007-03-07       Impact factor: 3.641

5.  Clostridium difficile infection: a surgical disease in evolution.

Authors:  Joshua L Hermsen; Cosmin Dobrescu; Kenneth A Kudsk
Journal:  J Gastrointest Surg       Date:  2008-07-09       Impact factor: 3.452

Review 6.  Update on the changing epidemiology of Clostridium difficile-associated disease.

Authors:  Lynne V McFarland
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-01

7.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

8.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

9.  Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients.

Authors:  Erik R Dubberke; Anne M Butler; Kimberly A Reske; Denis Agniel; Margaret A Olsen; Gina D'Angelo; L Clifford McDonald; Victoria J Fraser
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

10.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector.

Authors:  Raymond Hutubessy; Dan Chisholm; Tessa Tan-Torres Edejer
Journal:  Cost Eff Resour Alloc       Date:  2003-12-19
View more
  19 in total

1.  A Call for Greater Consideration for the Role of Vaccines in National Strategies to Combat Antibiotic-Resistant Bacteria: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 10, 2015.

Authors: 
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

2.  Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 3.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 5.  Healthcare-associated infections: potential for prevention through vaccination.

Authors:  E David G McIntosh
Journal:  Ther Adv Vaccines Immunother       Date:  2018-03-14

6.  Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.

Authors:  Reem Z Sharaiha; Daniel E Freedberg; Julian A Abrams; Y Claire Wang
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

7.  Optimal control of vaccination rate in an epidemiological model of Clostridium difficile transmission.

Authors:  Brittany Stephenson; Cristina Lanzas; Suzanne Lenhart; Judy Day
Journal:  J Math Biol       Date:  2017-05-08       Impact factor: 2.259

8.  Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities.

Authors:  Damon J A Toth; Lindsay T Keegan; Matthew H Samore; Karim Khader; Justin J O'Hagan; Holly Yu; Alvaro Quintana; David L Swerdlow
Journal:  Vaccine       Date:  2020-07-21       Impact factor: 3.641

9.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

10.  Vaccines for Healthcare-associated Infections: Promise and Challenge.

Authors:  Jane M Knisely; Baoying Liu; Ryan T Ranallo; Lanling Zou
Journal:  Clin Infect Dis       Date:  2016-05-20       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.